News articles about Glaukos (NYSE:GKOS) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Glaukos earned a news impact score of 0.18 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 45.1341048101492 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
GKOS has been the subject of several research reports. Cantor Fitzgerald set a $48.00 price target on shares of Glaukos and gave the company a “buy” rating in a report on Wednesday, December 27th. Stifel Nicolaus decreased their price target on shares of Glaukos from $42.00 to $39.00 and set a “buy” rating for the company in a report on Monday, February 26th. Stephens reaffirmed a “buy” rating and issued a $36.00 price target on shares of Glaukos in a report on Thursday, March 1st. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a report on Friday, March 23rd. Finally, Canaccord Genuity decreased their price target on shares of Glaukos from $48.00 to $43.00 and set a “buy” rating for the company in a report on Thursday, March 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $40.38.
Glaukos stock opened at $28.84 on Tuesday. The stock has a market cap of $959.54, a price-to-earnings ratio of 184.13 and a beta of 1.05. Glaukos has a 52-week low of $23.08 and a 52-week high of $48.89.
Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, February 28th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. The firm had revenue of $41.65 million during the quarter, compared to analyst estimates of $40.83 million. Glaukos had a negative net margin of 0.06% and a positive return on equity of 4.03%. The firm’s revenue was up 25.6% compared to the same quarter last year. equities research analysts predict that Glaukos will post -0.38 earnings per share for the current fiscal year.
In other Glaukos news, Director Jonathan Silverstein sold 464,583 shares of the business’s stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $32.29, for a total transaction of $15,001,385.07. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Orbimed Advisors Llc sold 836,500 shares of the business’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $32.02, for a total transaction of $26,784,730.00. The disclosure for this sale can be found here. Insiders own 16.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/17/glaukos-gkos-earning-somewhat-favorable-media-coverage-report-finds.html.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.